Zimmer Biomet Holdings, Inc. ZBH
At closeNov 5, 2026, 5:23 PM EST
After hours · Nov 5, 5:23 PM ET
- YTD
- +18.83%
- 1 year
- +22.04%
- Market cap
- 20.38B
- Revenue (ttm)
- 8.51B
- Profit margin
- 9.48%
- EPS (ttm)
- 3.96
- Shares out
- 190.74M
- P/E ratio
- 26.98
- Forward P/E
- 12.16
- Dividend
- 0.96 (0.99%)
- Ex-dividend date
- Sep 29, 2026
- YTD return
- +18.83%
- 1-year return
- +22.04%
- Volume
- 3.62M
- Avg volume
- 2.09M
- Open
- 111.00
- Previous close
- 110.15
- Day's range
- 105.50 – 111.16
- 52-week range
- 79.12 – 112.55
- Beta
- 0.47
- Analysts
- Buy
- Price target
- 106.90 (+0.1%)
- Earnings date
- Feb 9, 2027
1Y +18.34 (+20.72%)
Key statistics
- Enterprise value
- 25.66B
- PEG ratio
- 0.61
- Price / sales
- 2.47
- Price / book
- 1.66
- Dividend yield
- 0.99%
- Payout ratio
- 23.30%
- Revenue growth
- 4.80%
- Free cash flow
- 1.07B
- Total cash
- 464.50M
- Total debt
- 7.60B
- Return on equity
- 6.41%
- Short % of float
- 5.51%
- 50-day average
- 94.69
- 200-day average
- 91.72
Analyst view
Consensus: buy
- Target (low)
- 93.00
- Target (mean)
- 106.90
- Target (high)
- 130.00
- Strong buy2
- Buy6
- Hold19
- Sell0
- Strong sell0
Next earnings
Feb 9, 2027
Expected Feb 9, 2027. Consensus EPS estimate 1.88.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 9, 2027 | Dec 30, 2026 | 2.50 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 1.88 | 1.90 | +0.02 | +1.06% |
| Aug 5, 2026 | Jun 30, 2026 | 2.01 | 2.07 | +0.06 | +2.99% |
| Apr 28, 2026 | Mar 31, 2026 | 1.86 | 2.09 | +0.23 | +12.37% |
| Feb 10, 2026 | Dec 31, 2025 | 2.38 | 2.42 | +0.04 | +1.68% |
| Nov 5, 2025 | Sep 30, 2025 | 1.87 | 1.90 | +0.03 | +1.60% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 22, 2026 | Argus Research | reit | Buy | Buy |
| Oct 7, 2026 | Barclays | init | — | Equal-Weight |
| Aug 10, 2026 | Canaccord Genuity | main | Hold | Hold |
| Aug 7, 2026 | Truist Securities | main | Hold | Hold |
| Aug 6, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 6, 2026 | Bernstein | main | Market Perform | Market Perform |
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- zimmerbiomet.com
News
Citigroup Maintains Neutral on Zimmer Biomet Holdings, Raises Price Target to $117
RBC Capital Maintains Outperform on Zimmer Biomet Holdings, Raises Price Target to $125
Bernstein Maintains Market Perform on Zimmer Biomet Holdings, Raises Price Target to $107
Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term Wells Fargo Maintains Equal-Weight on Zimmer Biomet Holdings, Raises Price Target to $113
Zimmer Biomet Lifts Annual Growth Despite Challenging Knee Market
Zimmer Biomet Holdings, Inc. (ZBH) Q3 2026 Earnings Call Transcript
Zimmer Biomet Stock Up on Q3 Earnings & Revenue Beat, '26 View Up
Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Wayfair, Lendingtree, Bruker, Zimmer Biomet And Other Big Stocks Moving Higher On Wednesday
Your note
Sign in to keep a note on ZBH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEZJAK MARK | Officer | Conversion of Exercise of derivative security | Mar 5, 2025 | 13,134 |
| ELLINGSON RACHEL H. | Officer | Conversion of Exercise of derivative security | Feb 19, 2025 | 11,906 |
| NOOR JEHANZEB | Officer | Conversion of Exercise of derivative security | Mar 31, 2026 | 5,151 |
| PHIPPS CHAD F | Officer | Sale | Sep 3, 2026 | 65,231 |
| STELLATO PAUL A | Officer | Conversion of Exercise of derivative security | Mar 5, 2026 | 5,582 |
| TORNOS IVAN | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 5, 2026 | 83,191 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Inc. | 12.65% | 24,124,735 | 2.66B | Jun 29, 2026 |
| Blackrock Inc. | 8.19% | 15,614,847 | 1.72B | Jun 29, 2026 |
| Harris Associates L.P. | 6.68% | 12,738,025 | 1.40B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.62% | 12,634,937 | 1.39B | Jun 29, 2026 |
| Capital International Investors | 6.39% | 12,183,614 | 1.34B | Jun 29, 2026 |
| State Street Corporation | 4.65% | 8,877,171 | 977.51M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 8.15% | 15,549,900 | 1.71B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.22% | 6,141,461 | 676.27M | Jun 29, 2026 |
| VANGUARD WINDSOR FUNDS-Vanguard Windsor II Fund | 3.08% | 5,867,350 | 646.08M | Jul 30, 2026 |
| HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Fund | 2.95% | 5,621,292 | 618.99M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.63% | 5,010,793 | 551.76M | Jun 29, 2026 |
| WASHINGTON MUTUAL INVESTORS FUND | 2.42% | 4,610,277 | 507.66M | Sep 29, 2026 |
